Capivasertib: First Approved AKT inhibitor for the Treatment of Patients with Breast Cancer


Дәйексөз келтіру

Толық мәтін

Аннотация

Breast cancer frequently occurs in women. Among the several types of breast cancers, almost 50% of breast cancers are caused by one or more gene mutations of the PI3K/mTOR/AKT pathway. Capivasertib, the first AKT inhibitor, was authorized by the US FDA on November 16, 2023. It is used for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2 negative metastatic breast cancer with at least one alteration on PIK3CA/AKT1/PTEN. In this short perspective, Capivasertib’s physicochemical properties, synthesis, mechanism of action, binding mode, pharmacokinetics, drug interaction studies, and treatment-emergent adverse events are discussed.

Авторлар туралы

Surya De

Department of Chemistry,, Conju-Probe

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Әдебиет тізімі

  1. Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2024, 74(3), 229-263. doi: 10.3322/caac.21834 PMID: 38572751
  2. De, S.K. Fundamental of cancer detection, treatment, and prevention; Wiley, 2022, pp. 151-191. doi: 10.1002/9783527838561.ch6
  3. Moo, T.A.; Sanford, R.; Dang, C.; Morrow, M. Overview of breast cancer therapy. PET Clin., 2018, 13(3), 339-354. doi: 10.1016/j.cpet.2018.02.006 PMID: 30100074
  4. Trayes, K.P.; Cokenakes, S.E.H. Breast Cancer Treatment. Am. Fam. Physician, 2021, 104(2), 171-178. PMID: 34383430
  5. Singh, A.; Mishra, R.; Mazumder, A. Breast cancer and its therapeutic targets: A comprehensive review. Chem. Biol. Drug Des., 2024, 103(1), e14384. doi: 10.1111/cbdd.14384 PMID: 37919259
  6. Barile, E.; De, S.K.; Carlson, C.B.; Chen, V.; Knutzen, C.; Riel-Mehan, M.; Yang, L.; Dahl, R.; Chiang, G.; Pellecchia, M. Design, synthesis, and structure-activity relationships of 3-ethynyl-1H-indazoles as inhibitors of the phosphatidylinositol 3-kinase signaling pathway. J. Med. Chem., 2010, 53(23), 8368-8375. doi: 10.1021/jm100825h PMID: 21062009
  7. Ibanez, K.R.; Huang, T.T.; Lee, J.M. Combination therapy approach to overcome the resistance to PI3K pathway inhibitors in gynecological cancers. Cells, 2024, 13(12), 1064. doi: 10.3390/cells13121064 PMID: 38920692
  8. Zhang, H.; Jiang, R.; Zhu, J.; Sun, K.; Huang, Y.; Zhou, H.; Zheng, Y.; Wang, X. PI3K/AKT/mTOR signaling pathway: An important driver and therapeutic target in triple-negative breast cancer. Breast Cancer, 2024, 31(4), 539-551. doi: 10.1007/s12282-024-01567-5 PMID: 38630392
  9. Browne, I.M.; André, F.; Chandarlapaty, S.; Carey, L.A.; Turner, N.C. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncol., 2024, 25(4), e139-e151. doi: 10.1016/S1470-2045(23)00676-9 PMID: 38547898
  10. Wylaź, M.; Kaczmarska, A.; Pajor, D.; Hryniewicki, M.; Gil, D.; Dulińska-Litewka, J. Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer. Biomed. Pharmacother., 2023, 168, 115676. doi: 10.1016/j.biopha.2023.115676 PMID: 37832401
  11. Selvam, T.P.; Karthick, V.; Kumar, P.V.; Ali, M.A. Synthesis and structure-activity relationship study of 2-(substituted benzylidene)-7-(4-fluorophenyl)-5-(furan-2-yl)-2H-thiazolo3,2-apyrimidin-3(7H)-one derivatives as anticancer agents. Drug Discov. Ther., 2012, 6(4), 198-204. doi: 10.5582/ddt.2012.v6.4.198 PMID: 23006990
  12. Browne, I.M.; Okines, A.F.C. Resistance to targeted inhibitors of the PI3K/AKT/mTOR pathway in advanced oestrogen-receptor-positive breast cancer. Cancers (Basel), 2024, 16(12), 2259. doi: 10.3390/cancers16122259 PMID: 38927964
  13. Luboff, A.J.; DeRemer, D.L. Capivasertib: A novel AKT inhibitor approved for hormone-receptor-positive, HER-2-negative metastatic breast cancer. Ann. Pharmacother., 2024, 58(12), 1229-1237. doi: 10.1177/10600280241241531 PMID: 38566315
  14. López-Knowles, E.; O’Toole, S.A.; McNeil, C.M.; Millar, E.K.A.; Qiu, M.R.; Crea, P.; Daly, R.J.; Musgrove, E.A.; Sutherland, R.L. PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality. Int. J. Cancer, 2010, 126(5), 1121-1131. doi: 10.1002/ijc.24831 PMID: 19685490
  15. Csolle, M.P.; Ooms, L.M.; Papa, A.; Mitchell, C.A. PTEN and other PtdIns(3,4,5)P3 lipid phosphatases in breast cancer. Int. J. Mol. Sci., 2020, 21(23), 9189. doi: 10.3390/ijms21239189 PMID: 33276499
  16. Turner, N.C.; Oliveira, M.; Howell, S.J.; Dalenc, F.; Cortes, J.; Gomez Moreno, H.L.; Hu, X.; Jhaveri, K.; Krivorotko, P.; Loibl, S.; Morales Murillo, S.; Okera, M.; Park, Y.H.; Sohn, J.; Toi, M.; Tokunaga, E.; Yousef, S.; Zhukova, L.; de Bruin, E.C.; Grinsted, L.; Schiavon, G.; Foxley, A.; Rugo, H.S. Capivasertib in hormone receptor–positive advanced breast cancer. N. Engl. J. Med., 2023, 388(22), 2058-2070. doi: 10.1056/NEJMoa2214131 PMID: 37256976
  17. Smyth, L.M.; Tamura, K.; Oliveira, M.; Ciruelos, E.M.; Mayer, I.A.; Sablin, M.P.; Biganzoli, L.; Ambrose, H.J.; Ashton, J.; Barnicle, A.; Cashell, D.D.; Corcoran, C.; de Bruin, E.C.; Foxley, A.; Hauser, J.; Lindemann, J.P.O.; Maudsley, R.; McEwen, R.; Moschetta, M.; Pass, M.; Rowlands, V.; Schiavon, G.; Banerji, U.; Scaltriti, M.; Taylor, B.S.; Chandarlapaty, S.; Baselga, J.; Hyman, D.M. Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1 E17K-mutant, er-positive metastatic breast cancer. Clin. Cancer Res., 2020, 26(15), 3947-3957. doi: 10.1158/1078-0432.CCR-19-3953 PMID: 32312891
  18. Smyth, L.M.; Batist, G.; Meric-Bernstam, F.; Kabos, P.; Spanggaard, I.; Lluch, A.; Jhaveri, K.; Varga, A.; Wong, A.; Schram, A.M.; Ambrose, H.; Carr, T.H.; de Bruin, E.C.; Salinas-Souza, C.; Foxley, A.; Hauser, J.; Lindemann, J.P.O.; Maudsley, R.; McEwen, R.; Moschetta, M.; Nikolaou, M.; Schiavon, G.; Razavi, P.; Banerji, U.; Baselga, J.; Hyman, D.M.; Chandarlapaty, S. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. NPJ Breast Cancer, 2021, 7(1), 44. doi: 10.1038/s41523-021-00251-7 PMID: 33863913
  19. Andrikopoulou, A.; Chatzinikolaou, S.; Panourgias, E.; Kaparelou, M.; Liontos, M.; Dimopoulos, M.A.; Zagouri, F. The emerging role of capivasertib in breast cancer. Breast, 2022, 63, 157-167. doi: 10.1016/j.breast.2022.03.018 PMID: 35398754
  20. Addie, M.; Ballard, P.; Buttar, D.; Crafter, C.; Currie, G.; Davies, B.R.; Debreczeni, J.; Dry, H.; Dudley, P.; Greenwood, R.; Johnson, P.D.; Kettle, J.G.; Lane, C.; Lamont, G.; Leach, A.; Luke, R.W.A.; Morris, J.; Ogilvie, D.; Page, K.; Pass, M.; Pearson, S.; Ruston, L. Discovery of 4-Amino- N -(1 S)-1-(4-chlorophenyl)-3-hydroxypropyl-1-(7 H -pyrrolo2,3- dpyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of akt kinases. J. Med. Chem., 2013, 56(5), 2059-2073. doi: 10.1021/jm301762v PMID: 23394218
  21. Wang, Y.T.; Yang, P.C.; Zhang, Y.F.; Sun, J.F. Synthesis and clinical application of new drugs approved by FDA in 2023. Eur. J. Med. Chem., 2024, 265, 116124. doi: 10.1016/j.ejmech.2024.116124 PMID: 38183778
  22. Miller, C.; Wild, M.; Zhang, Z.; Sommavilla, R.; Shanahan, D.; Bailey, C.; Gränfors, M.; Bragg, R.A.; Dong, J.; Sidhu, S.; Cullberg, M. A Phase I study to determine the absolute bioavailability and absorption, distribution, metabolism, and excretion of capivasertib in healthy male participants. Drug Metab. Dispos., 2024, 52(9), 939-948. doi: 10.1124/dmd.124.001636
  23. Fernandez-Teruel, C.; Cullberg, M.; Eberlein, C.; Barry, S.T.; Zhou, D. Population pharmacokinetics of capivasertib in patients with advanced or metastatic solid tumours. Clin. Pharmacokinet., 2024, 63(8), 1191-1204. doi: 10.1007/s40262-024-01407-x PMID: 39127854
  24. De, S.K. Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome. Front. Pharmacol., 2024, 15, 1337436. doi: 10.3389/fphar.2024.1337436 PMID: 38410131
  25. Rescigno, P.; Porta, N.; Finneran, L.; Riisnaes, R.; Figueiredo, I.; Carreira, S.; Flohr, P.; Miranda, S.; Bertan, C.; Ferreira, A.; Crespo, M.; Rodrigues, D.N.; Gurel, B.; Nobes, J.; Crabb, S.; Malik, Z.; Ralph, C.; McGovern, U.; Hoskin, P.; Jones, R.J.; Birtle, A.; Gale, J.; Sankey, P.; Jain, S.; McLaren, D.; Chadwick, E.; Espinasse, A.; Hall, E.; de Bono, J. Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. Eur. J. Cancer, 2024, 205, 114103. doi: 10.1016/j.ejca.2024.114103 PMID: 38729054
  26. Eberlein, C.; Williamson, S.C.; Hopcroft, L.; Ros, S.; Moss, J.I.; Kerr, J.; van Weerden, W.M.; de Bruin, E.C.; Dunn, S.; Willis, B.; Ross, S.J.; Rooney, C.; Barry, S.T. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. Br. J. Cancer, 2024, 130(8), 1377-1387. doi: 10.1038/s41416-024-02614-w PMID: 38396173
  27. Crabb, S.J.; Griffiths, G.; Marwood, E.; Dunkley, D.; Downs, N.; Martin, K.; Light, M.; Northey, J.; Wilding, S.; Whitehead, A.; Shaw, E.; Birtle, A.J.; Bahl, A.; Elliott, T.; Westbury, C.; Sundar, S.; Robinson, A.; Jagdev, S.; Kumar, S.; Rooney, C.; Salinas-Souza, C.; Stephens, C.; Khoo, V.; Jones, R.J. Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: A randomized, placebo-controlled phase ii trial (ProCAID). J. Clin. Oncol., 2021, 39(3), 190-201. doi: 10.1200/JCO.20.01576 PMID: 33326257
  28. Yap, T.A.; Kristeleit, R.; Michalarea, V.; Pettitt, S.J.; Lim, J.S.J.; Carreira, S.; Roda, D.; Miller, R.; Riisnaes, R.; Miranda, S.; Figueiredo, I.; Rodrigues, D.N.; Ward, S.; Matthews, R.; Parmar, M.; Turner, A.; Tunariu, N.; Chopra, N.; Gevensleben, H.; Turner, N.C.; Ruddle, R.; Raynaud, F.I.; Decordova, S.; Swales, K.E.; Finneran, L.; Hall, E.; Rugman, P.; Lindemann, J.P.O.; Foxley, A.; Lord, C.J.; Banerji, U.; Plummer, R.; Basu, B.; Lopez, J.S.; Drew, Y.; de Bono, J.S.; Phase, I. Phase I trial of the PARP inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 - and non– BRCA1/2 -mutant cancers. Cancer Discov., 2020, 10(10), 1528-1543. doi: 10.1158/2159-8290.CD-20-0163 PMID: 32532747
  29. Westin, S.N.; Labrie, M.; Litton, J.K.; Blucher, A.; Fang, Y.; Vellano, C.P.; Marszalek, J.R.; Feng, N.; Ma, X.; Creason, A.; Fellman, B.; Yuan, Y.; Lee, S.; Kim, T.B.; Liu, J.; Chelariu-Raicu, A.; Chen, T.H.; Kabil, N.; Soliman, P.T.; Frumovitz, M.; Schmeler, K.M.; Jazaeri, A.; Lu, K.H.; Murthy, R.; Meyer, L.A.; Sun, C.C.; Sood, A.K.; Coleman, R.L.; Mills, G.B. Phase Ib dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple-negative breast, and ovarian cancer. Clin. Cancer Res., 2021, 27(23), 6354-6365. doi: 10.1158/1078-0432.CCR-21-1656 PMID: 34518313

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bentham Science Publishers, 2025